News 12.08.2025 Schlieren/Zurich, Switzerland, August 12, 2025 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a...
News 12.08.2025 Topadur Pharma AG, a Swiss biopharmaceutical company developing innovative therapies for aging-related diseases, announces the appointment of Professor Thierry Carrel, MD, to its Board of Directors. Professor Carrel is one of Switzerland’s most accomplished cardiac surgeons. His expertise in clinical needs, regulatory navigation, and innovative technologies will provide strategic direction...
News 05.08.2025 Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine...
News 28.07.2025 Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, announces a change in its Executive Committee. Peter Freisler will join Siegfried as Chief Business Officer and become a member of the Executive Committee, effective August 1, 2025. He succeeds Marianne Späne who has decided to step...
News 23.07.2025 Schlieren / Zurich, Switzerland, 22 July, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has published preclinical data in PLOS Pathogens demonstrating the discovery and characterization of its lead clinical asset, potravitug, a highly potent human monoclonal antibody, neutralizing...